GC Biopharma
VC Fund
Gyeongju, South Korea
GC Biopharma is a VC fund in Gyeongju focused on Health Care and Biotechnology. GC holding company, which operates pharmaceutical, biotechnology, distribution system, life insurance, and healthcare entities.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries GC Biopharma invests in
Stages GC Biopharma invests in
Countries GC Biopharma invests in
Round sizes
Round size
- Seed
- $765k–$12M
- Series A
- $2.6M–$78M
- Series B
- $12M–$120M
Investment Focus
Industry
- Health Care 5 (25%)
- Biotechnology 5 (25%)
- Medical 4 (20%)
- Therapeutics 2 (10%)
- Pharmaceutical 2 (10%)
Stage
- Series A 6 (30%)
- Series B 6 (30%)
- Seed 4 (20%)
- Series C 1 (5%)
- Funding Round 1 (5%)
Country
- South Korea 10 (50%)
- Canada 1 (5%)
- United States 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Curevo
|
Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $110M / Series B / Mar 17, 2025 | |
Feldan Therapeutics
|
Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $16.5M / Series B / Jun 13, 2023 | |
Humanscape
|
Humanscape is a rare disease health-tech company working to bring better chances of cure for patients. By collecting comprehensive patient health data from genotype, clinical to phenotype data and systematically compiling it into a complete, ready-to-use data set, pharmaceuticals and researchers can significantly reduce both time and cost for newdrug development. | $14.9M / Series C / May 12, 2023 | |
|
Curevo
|
Curevo is a clinical-stage biotech firm focused on producing next-generation vaccines that brings effectiveness, safety, tolerability, and advanced production capabilities to the market. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and thedesired immune responses. They are targeting a unique position in the $7B Varicella Zoster Virus vaccine market. | $26M / Series A / Nov 16, 2022 | |
Nex Eye
|
Nex Eye is an innovative biotechnology firm that offers revolutionary immunotherapy solutions for individuals battling cancer. The company addresses the fundamental reasons behind the failure of immunotherapy, which are influenced by the biology of cancer itself. Utilizing its ON-SMRT® platform based on actual patient data and resistant cancermodels, Nex Eye identifies new immune-evasion targets such as ONCOKINE®. By transforming the approach to tackling immune resistance, the firm is pioneering a new era in cancer therapy by revitalizing the capabilities of the immune system. | $15.4M / Series A / Oct 07, 2022 | |
Money Walk
|
Money Walk is a novel pedometer program that allows users to earn money simply by walking.' Creddy,' the yellow companion who loves to walk, will look after your health and your wallet. Install the Money Walk app right now and you'll be able to catch both health and money. | $764.7K / Seed / Aug 01, 2022 | |
Pumpkin Company
|
Pumpkin Company is a animal start-up that provide various services such as cafe, kindergarten, day care, beauty, and hoteling. | Seed / Jul 21, 2022 | |
Emocog
|
Emocog is a developer of digital medical software focused on the assessment and management of emotional and cognitive conditions. It develops software medical devices, including Cogthera for mild cognitive impairment. The company’s products are intended to support the evaluation and monitoring of cognitive function across stages associated withdementia, including early detection and ongoing symptom tracking. | $12.2M / Seed / Mar 25, 2022 | |
MiNDCAFE
|
MiNDCAFE is an online psychological counseling and mind-healing platform. They also provide online counseling that is effective in reducing psychological symptoms and has the advantages of being easily accessible, efficient, and anonymous. | $17M / Series B / Feb 10, 2022 | |
Cyrus Therapeutics
|
Cyrus Therapeutics is a biotechnology company that discovers and develops molecule medicines to conquer chronic diseases. | $24.1M / Series B / Jan 27, 2022 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does GC Biopharma invest in?
GC Biopharma invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is GC Biopharma's check size?
GC Biopharma typically joins rounds of $765k–$12M at Seed, $2.6M–$78M at Series A and $12M–$120M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GC Biopharma participates in.
When did GC Biopharma last invest?
The most recent investment recorded for GC Biopharma closed in Mar 2025. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
